Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cobamamide→

Cobamamide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
13870-90-1
Molecular formula
C72H100CoN18O17P
Molecular weight
1579.6 g/mol
Drug class
Adenosylcobalamin (coenzyme B12)vitamin B12 coenzyme
Mechanism of action
Acts as a cofactor for methylmalonyl-CoA mutase, supporting conversion of methylmalonyl-CoA to succinyl-CoA in mitochondrial metabolism. It is one of the active coenzyme forms of vitamin B12.
Indications / reported uses
  • Replacement of vitamin B12 coenzyme activity in selected deficiency states or inherited cobalamin-processing disorders in countries where cobamamide products are authorised; formulation and route-specific evidence should be checked

Sources: NIH Office of Dietary Supplements — Vitamin B12 fact sheet · NLM MeSH — Adenosylcobalamin · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cobamamide Environmental Risk Assessment (ERA) (the Cobamamide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.